Cargando…

Fabrication of An Immunostimulatory Supramolecular Nanomedicine for Potent Cancer Chemoimmunotherapy

[Image: see text] Chemoimmunotherapy can boost strong antitumor immune responses by triggering immunogenic cell death (ICD), which highlights a promising prospect in clinical applications. However, current chemoimmunotherapy shows limited efficacy due to the low delivery efficiency and insufficient...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xinyang, Qi, Shaolong, Cao, Fangfang, Yang, Kai, Li, Hongjian, Peng, Kun, Liu, Zhida, Bai, Bing, Buljan, Marija, Chen, Xiaoyuan, Yu, Guocan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685430/
https://www.ncbi.nlm.nih.gov/pubmed/38034980
http://dx.doi.org/10.1021/jacsau.3c00515
_version_ 1785151628922322944
author Yu, Xinyang
Qi, Shaolong
Cao, Fangfang
Yang, Kai
Li, Hongjian
Peng, Kun
Liu, Zhida
Bai, Bing
Buljan, Marija
Chen, Xiaoyuan
Yu, Guocan
author_facet Yu, Xinyang
Qi, Shaolong
Cao, Fangfang
Yang, Kai
Li, Hongjian
Peng, Kun
Liu, Zhida
Bai, Bing
Buljan, Marija
Chen, Xiaoyuan
Yu, Guocan
author_sort Yu, Xinyang
collection PubMed
description [Image: see text] Chemoimmunotherapy can boost strong antitumor immune responses by triggering immunogenic cell death (ICD), which highlights a promising prospect in clinical applications. However, current chemoimmunotherapy shows limited efficacy due to the low delivery efficiency and insufficient immunogenicity of available chemotherapeutic drugs. A supramolecular polymeric nanomedicine (Pt-Tu@NP) is herein reported using cucurbit[7]uril-based host–guest recognition and noncovalent self-assembly. Pt-Tu@NPs have excellent biodistribution and strongly evoke the endoplasmic reticulum stress-mediated ICD of tumor cells, triggering potent antitumor immune responses by promoting dendritic cell (DC) maturation and cytotoxic T cell infiltration. The coordinated butyrate promotes a positive feedback regulation between DCs and CD8(+) T cells. Pt-Tu@NPs stimulate immune cold tumors into hot ones, working in synergy with an immune checkpoint blockade to effectively suppress tumor growth and metastasis, which suggests a promising approach for cancer chemoimmunotherapy.
format Online
Article
Text
id pubmed-10685430
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-106854302023-11-30 Fabrication of An Immunostimulatory Supramolecular Nanomedicine for Potent Cancer Chemoimmunotherapy Yu, Xinyang Qi, Shaolong Cao, Fangfang Yang, Kai Li, Hongjian Peng, Kun Liu, Zhida Bai, Bing Buljan, Marija Chen, Xiaoyuan Yu, Guocan JACS Au [Image: see text] Chemoimmunotherapy can boost strong antitumor immune responses by triggering immunogenic cell death (ICD), which highlights a promising prospect in clinical applications. However, current chemoimmunotherapy shows limited efficacy due to the low delivery efficiency and insufficient immunogenicity of available chemotherapeutic drugs. A supramolecular polymeric nanomedicine (Pt-Tu@NP) is herein reported using cucurbit[7]uril-based host–guest recognition and noncovalent self-assembly. Pt-Tu@NPs have excellent biodistribution and strongly evoke the endoplasmic reticulum stress-mediated ICD of tumor cells, triggering potent antitumor immune responses by promoting dendritic cell (DC) maturation and cytotoxic T cell infiltration. The coordinated butyrate promotes a positive feedback regulation between DCs and CD8(+) T cells. Pt-Tu@NPs stimulate immune cold tumors into hot ones, working in synergy with an immune checkpoint blockade to effectively suppress tumor growth and metastasis, which suggests a promising approach for cancer chemoimmunotherapy. American Chemical Society 2023-11-07 /pmc/articles/PMC10685430/ /pubmed/38034980 http://dx.doi.org/10.1021/jacsau.3c00515 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Yu, Xinyang
Qi, Shaolong
Cao, Fangfang
Yang, Kai
Li, Hongjian
Peng, Kun
Liu, Zhida
Bai, Bing
Buljan, Marija
Chen, Xiaoyuan
Yu, Guocan
Fabrication of An Immunostimulatory Supramolecular Nanomedicine for Potent Cancer Chemoimmunotherapy
title Fabrication of An Immunostimulatory Supramolecular Nanomedicine for Potent Cancer Chemoimmunotherapy
title_full Fabrication of An Immunostimulatory Supramolecular Nanomedicine for Potent Cancer Chemoimmunotherapy
title_fullStr Fabrication of An Immunostimulatory Supramolecular Nanomedicine for Potent Cancer Chemoimmunotherapy
title_full_unstemmed Fabrication of An Immunostimulatory Supramolecular Nanomedicine for Potent Cancer Chemoimmunotherapy
title_short Fabrication of An Immunostimulatory Supramolecular Nanomedicine for Potent Cancer Chemoimmunotherapy
title_sort fabrication of an immunostimulatory supramolecular nanomedicine for potent cancer chemoimmunotherapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685430/
https://www.ncbi.nlm.nih.gov/pubmed/38034980
http://dx.doi.org/10.1021/jacsau.3c00515
work_keys_str_mv AT yuxinyang fabricationofanimmunostimulatorysupramolecularnanomedicineforpotentcancerchemoimmunotherapy
AT qishaolong fabricationofanimmunostimulatorysupramolecularnanomedicineforpotentcancerchemoimmunotherapy
AT caofangfang fabricationofanimmunostimulatorysupramolecularnanomedicineforpotentcancerchemoimmunotherapy
AT yangkai fabricationofanimmunostimulatorysupramolecularnanomedicineforpotentcancerchemoimmunotherapy
AT lihongjian fabricationofanimmunostimulatorysupramolecularnanomedicineforpotentcancerchemoimmunotherapy
AT pengkun fabricationofanimmunostimulatorysupramolecularnanomedicineforpotentcancerchemoimmunotherapy
AT liuzhida fabricationofanimmunostimulatorysupramolecularnanomedicineforpotentcancerchemoimmunotherapy
AT baibing fabricationofanimmunostimulatorysupramolecularnanomedicineforpotentcancerchemoimmunotherapy
AT buljanmarija fabricationofanimmunostimulatorysupramolecularnanomedicineforpotentcancerchemoimmunotherapy
AT chenxiaoyuan fabricationofanimmunostimulatorysupramolecularnanomedicineforpotentcancerchemoimmunotherapy
AT yuguocan fabricationofanimmunostimulatorysupramolecularnanomedicineforpotentcancerchemoimmunotherapy